Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?

Infliximab (IFX) is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha. It is currently approved for the treatment of certain rheumatic diseases or inflammatory bowel diseases. Clinical studies have suggested that monitoring IFX concentrations could improve treatment response. Howe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Analytical and bioanalytical chemistry 2017-02, Vol.409 (5), p.1195-1205
Hauptverfasser:	Jourdil, Jean-Francois, Lebert, Dorothée, Gautier-Veyret, Elodie, Lemaitre, Florian, Bonaz, Bruno, Picard, Guillaume, Tonini, Julia, Stanke-Labesque, Françoise
Format:	Artikel
Sprache:	eng
Schlagworte:	Analytical Chemistry Antibodies Assaying Biochemistry Blood plasma Bowel disease Characterization and Evaluation of Materials Chemical properties Chemistry Chemistry and Materials Science Chromatography Chromatography, Liquid Composition ELISA Enzyme-Linked Immunosorbent Assay Food Science Humans Immunoassay Infliximab Laboratories Laboratory Medicine Life Sciences Liquid chromatography Liquids Mass spectrometry Measurement Medical services Methods Monitoring Monitoring/Environmental Analysis Peptides Pharmaceutical sciences Pharmacology Plasma Proteomics Research Paper Scientific imaging Tandem Mass Spectrometry Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!